Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | WNT3A | P56704 | 4/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407936 | 0.84 | MAPT (0.52) | POLBRORCMAPTTP53ROCK2 | |
| SCHEMBL1407961 | 0.83 | MAPT (0.48) | POLBRORCMAPTTP53ROCK2 | |
| SCHEMBL1408502 | 0.81 | AURKA (0.55) | POLBMAPTTP53P2RY14RET | |
| SCHEMBL1408584 | 0.80 | MAPT (0.46) | POLBRORCMAPTTP53ROCK2 | |
| SCHEMBL1408415 | 0.77 | MAPT (0.43) | POLBRORCMAPTTP53ROCK2 | |
| SCHEMBL1408513 | 0.77 | MAPT (0.45) | POLBRORCMAPTTP53ROCK2 | |
| SCHEMBL1408439 | 0.77 | ABL1 (0.55) | RET | |
| SCHEMBL1407966 | 0.77 | MKNK2 (0.63) | RET | |
| SCHEMBL2497536 | 0.75 | MEN1 (0.41) | POLBRORCMAPTTP53 | |
| SCHEMBL1408435 | 0.75 | MCHR1 (0.44) | RORCMAPTTP53WNT3AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101198607-A | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2008-06-11 | — | — | CN | claimed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | POLB 1724/4885RORC 2712/4885MAPT 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.